[Cardiac complications following allogeneic hematopoietic stem cell transplantation: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)].

[1]  E. Shpall,et al.  Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era , 2021, Blood advances.

[2]  L. Thomas,et al.  The utility of strain imaging in the cardiac surveillance of bone marrow transplant patients , 2021, Heart.

[3]  A. Vekhoff,et al.  Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation , 2021, JACC. CardioOncology.

[4]  A. Cohen-Solal,et al.  Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology , 2020, European journal of heart failure.

[5]  J. Zamorano,et al.  Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  M. Labopin,et al.  Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. , 2020, Clinical lymphoma, myeloma & leukemia.

[7]  Dae Hyun Lee,et al.  Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). , 2019, Journal of the American College of Cardiology.

[8]  M. Sorror,et al.  Moderate or severe valvular heart disease and outcomes in allogeneic stem cell transplantation. , 2019, International journal of cardiology.

[9]  C. Lima,et al.  Persistent heart failure following melphalan and fludarabine conditioning. , 2019, Journal of Cardiology Cases.

[10]  Tochukwu M Okwuosa,et al.  Pretransplant Cardiac Evaluation Using Novel Technology , 2019, Journal of clinical medicine.

[11]  W. Leisenring,et al.  Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. , 2018, Blood advances.

[12]  P. Westervelt,et al.  Cardiomyopathy in patients after posttransplant cyclophosphamide–based hematopoietic cell transplantation , 2017, Cancer.

[13]  M. D. Taylor,et al.  The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults , 2017, Bone Marrow Transplantation.

[14]  K. Ohashi,et al.  The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) , 2016, Annals of Hematology.

[15]  A. Blaes,et al.  Cardiovascular Complications of Hematopoietic Stem Cell Transplantation , 2016, Current Treatment Options in Cardiovascular Medicine.

[16]  K. Kuliczkowski,et al.  Echocardiographic evaluation of the early cardiotoxic effect of hematopoietic stem cell transplantation in patients with hematologic malignancies , 2016, Leukemia & lymphoma.

[17]  I. Yakoub-Agha,et al.  [How we harmonize HSCT clinical practices among the SFGM-TC centers]. , 2016, Bulletin du cancer.

[18]  R. Shanley,et al.  Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center , 2015, Bone Marrow Transplantation.

[19]  R. Gale,et al.  Arrhythmias in the Setting of Hematopoietic Cell Transplants , 2015, Bone Marrow Transplantation.

[20]  S. Parmar,et al.  Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma , 2015, Leukemia & lymphoma.

[21]  D. Weisdorf,et al.  Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done? , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  Scott D Flamm,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[23]  S. Bhatia,et al.  Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  M. Sorror.  How I assess comorbidities before hematopoietic cell transplantation. , 2013, Blood.

[25]  C. Tzeng,et al.  Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation—association with chronic GVHD in late-onset adult patients , 2012, Annals of Hematology.

[26]  R. Mertelsmann,et al.  NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantation , 2012, Annals of Hematology.

[27]  S. Bhatia,et al.  Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. , 2011, Blood.

[28]  D. Friedman,et al.  Cardiovascular Hospitalizations and Mortality Among Recipients of Hematopoietic Stem Cell Transplantation , 2011, Annals of Internal Medicine.

[29]  T. Braun,et al.  Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation , 2010, Bone Marrow Transplantation.

[30]  U. Popat,et al.  Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  S. Bhatia,et al.  Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation , 2008, British journal of haematology.

[32]  A. Nademanee,et al.  Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. , 2007, Blood.

[33]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[34]  M. Loriaux,et al.  Acute graft‐versus‐host disease of the heart , 2006, Pediatric blood & cancer.

[35]  J. Hartikainen,et al.  Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation , 2005, Bone Marrow Transplantation.

[36]  K. Schultz,et al.  Cardiac manifestations of graft-versus-host disease. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  A. Nademanee,et al.  Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. , 2005, Blood.

[38]  P. Morandi,et al.  Cardiac toxicity of high-dose chemotherapy , 2005, Bone Marrow Transplantation.

[39]  K. Ohta,et al.  Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation , 2004, American journal of hematology.

[40]  F. Lionnet,et al.  Acute myocardial ischemia after high-dose therapy with BEAM regimen , 2002, Bone Marrow Transplantation.

[41]  D. Weisdorf,et al.  Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997 , 2001, Bone Marrow Transplantation.

[42]  J. Szer,et al.  Acute left ventricular failure following melphalan and fludarabine conditioning , 2001, Bone Marrow Transplantation.

[43]  K. Klingel,et al.  Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin , 2001, Bone Marrow Transplantation.

[44]  M. Goldberg,et al.  Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. , 1986, Blood.